229016-73-3

Basic information

• Product Name: PyridiniuM, 4-[2-[[(6R,7R)-2-carboxy-7-[[(2Z)-2-(ethoxyiMino)-2-[5-(phosphonoaMino)-1,2,4-thiadiazol-3-yl]acetyl]aMino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-Methyl-, inner salt
• Synonyms: PyridiniuM, 4-[2-[[(6R,7R)-2-carboxy-7-[[(2Z)-2-(ethoxyiMino)-2-[5-(phosphonoaMino)-1,2,4-thiadiazol-3-yl]acetyl]aMino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-Methyl-, inner salt;Ceftaroline FosaMil Inner salt;Ceftaroline Fosamil Impurity 4;4-[2-[[(6R,7R)-2-Carboxy-7-[[(2Z)-(ethoxyimino)[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-methylpyridinium inner salt;4-[2-[[(6R,7R)-2-Carboxy-7-[[(2Z)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-methyl-pyridinium Inner Salt
• CAS NO: 229016-73-3
• Molecular Formula: C22H21N8O8PS4
• Molecular Weight: 684.684701
• Mol File: 229016-73-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: PyridiniuM, 4-[2-[[(6R,7R)-2-carboxy-7-[[(2Z)-2-(ethoxyiMino)-2-[5-(phosphonoaMino)-1,2,4-thiadiazol-3-yl]acetyl]aMino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-Methyl-, inner salt(CAS DataBase Reference)
• NIST Chemistry Reference: PyridiniuM, 4-[2-[[(6R,7R)-2-carboxy-7-[[(2Z)-2-(ethoxyiMino)-2-[5-(phosphonoaMino)-1,2,4-thiadiazol-3-yl]acetyl]aMino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-Methyl-, inner salt(229016-73-3)
• EPA Substance Registry System: PyridiniuM, 4-[2-[[(6R,7R)-2-carboxy-7-[[(2Z)-2-(ethoxyiMino)-2-[5-(phosphonoaMino)-1,2,4-thiadiazol-3-yl]acetyl]aMino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-Methyl-, inner salt(229016-73-3)

Safety Data

• Hazardous Substances Data: 229016-73-3(Hazardous Substances Data)

Usage

Uses

1. Used in Pharmaceutical Industry:
PyridiniuM, 4-[2-[[(6R,7R)-2-carboxy-7-[[(2Z)-2-(ethoxyiMino)-2-[5-(phosphonoaMino)-1,2,4-thiadiazol-3-yl]acetyl]aMino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-Methyl-, inner salt is used as a pharmaceutical compound for its potential therapeutic properties. Its complex structure and functional groups may allow it to interact with specific biological targets, making it a candidate for the development of new drugs.
2. Used in Chemical Research:
In the field of chemical research, PyridiniuM, 4-[2-[[(6R,7R)-2-carboxy-7-[[(2Z)-2-(ethoxyiMino)-2-[5-(phosphonoaMino)-1,2,4-thiadiazol-3-yl]acetyl]aMino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-Methyl-, inner salt can be utilized as a starting material or intermediate in the synthesis of other complex molecules. Its unique structure may provide new insights into chemical reactions and mechanisms, leading to the discovery of novel compounds with various applications.
3. Used in Material Science:
PyridiniuM, 4-[2-[[(6R,7R)-2-carboxy-7-[[(2Z)-2-(ethoxyiMino)-2-[5-(phosphonoaMino)-1,2,4-thiadiazol-3-yl]acetyl]aMino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-Methyl-, inner salt may also find applications in material science due to its potential to form novel materials with unique properties. Its chemical structure could be exploited to create new materials with specific characteristics, such as improved stability, reactivity, or selectivity.

Upstream product

• 1602493-17-3 Cl^(1-)*C₁₉H₂₃N₄O₃S₃Si⁽¹⁺⁾ 
• 90211-01-1 2-[[5-(dichlorophosphinyl)amino]-1,2,4-thiadiazole-3-yl]-2(Z)-ethoxyiminoacetyl chloride 
• 400827-68-1 4-(2-{[(6R,7R)-2-[(diphenylmethoxy)carbonyl]-8-oxo-7-(2-phenylacetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]sulfanyl}-1,3-thiazol-4-yl)pyridine 
• 77168-63-9 [4-(4-pyridyl)-1,3-thiazol-2-yl]thiol 
• 92096-37-2 benzhydryl (6R,7R)-7β-[(phenylacetyl)amino]-3-[(methylsulfonyl)oxy]-3-cephem-4-carboxylate 

Relevant articles and documents

Preparation method of ceftaroline fosamil

The invention belongs to the field of pharmaceutical chemistry and specifically relates to a preparation method of ceftaroline fosamil. The method includes the following steps: subjecting (Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-ethoxyimidoacetic acid being a raw material and halotriphenylmethane to an amidogen protecting reaction in an alkaline environment to obtain a compound represented by formula I; subjecting the compound represented by formula I and 2,4,6-trinitrofluorobenzene to a substitution reaction under alkaline condition to obtain a compound represented by formula II; subjecting the compound represented by formula II and a compound represented by formula III to an acylation reaction under alkaline condition to obtain a compound represented by formula IV; removing a triphenylmethyl group from the compound represented by formula IV under acidic condition or under catalytic hydrogenation condition to obtain a compound represented by formula V; and subjecting the compound represented by formula V and a phosphorylation reagent to a phosphorylation reaction to obtain the ceftaroline fosamil. According to the method, the obtained ceftaroline fosamil has less impurities and a high yield. The effect is significantly better than that of the prior art.

NOVEL CRYSTALLINE FORMS OF CEFTAROLINE FOSAMIL

The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation. Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and β-lactamase inhibitors.

NOVEL PROCESS FOR PREPARING CEFTAROLINE FOSAMIL

The present invention relates to a novel process for preparing ceftaroline fosamil as well as to intermediates of this process.

TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: Synthesis, physicochemical and pharmacological properties

Crystalline 1 (TAK-599) is a novel N-phosphono prodrug of anti-methicillin-resistant Staphylococcus aureus (MRSA) cephalosporin 2a (T-91825) that has high affinity for penicillin-binding protein (PBP) 2′ (IC50; 0.90 μg/mL) and shows potent in v